亨丁頓舞蹈症治療藥的全球市場:藥物的類別(認證核可藥，仿單標示外醫藥品)·各流通管道(醫院藥局，線上藥局，零售藥局)·各地區的評估，機會及預測 (2018～2032年)

全球亨廷頓舞蹈症藥物市場預計將從2024年的5.0956億美元增長到2032年的13.0278億美元，預測期內（2025-2032年）的複合年增長率為12.45%。市場成長的驅動力包括：亨廷頓舞蹈症患者數量的增加、藥物和治療投入的增加、提高公眾對亨廷頓舞蹈症認識的舉措的增多以及醫學研究的快速進步。根據加州大學戴維斯分校健康中心估計，全球每1萬人中約有1人患有亨廷頓舞蹈症。基因治療和RNA治療的最新進展也推動了市場的擴張。

此外，政府和非營利組織正在促進患者和照護者之間的合作，以提高他們對臨床試驗的認識。這些努力不僅提高了臨床試驗的參與率，也加快了藥物研發的進度。此外，醫療保健專業人員對正在進行的臨床研究和神經退化性疾病診斷技術的進步的認識不斷提高，也推動了市場的成長。對疾病修飾療法的投資不斷增加，以及政府對罕見疾病管理的支持不斷增加，也促進了市場的擴張。

目錄

第1章 計劃的範圍和定義

第2章 分析方法

第3章 美國的關稅的影響

第4章 摘要整理

第5章 全球亨丁頓舞蹈症治療藥市場未來展望 (2018～2032年)

• 市場規模的分析與預測
  • 以金額為準
• 市場佔有率的分析與預測
  • 藥物的類別
    • 認證核可藥
    • 仿單標示外醫藥品
  • 各流通管道
    • 醫院藥局
    • 線上藥局
    • 零售藥局
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場佔有率分析:各企業(前五名公司以及其他，以金額為準，2024年)
• 市場地圖分析(2024年)
  • 藥物的類別
  • 各流通管道
  • 各地區

第6章 北美的亨丁頓舞蹈症治療藥市場未來展望 (2018～2032年)

• 市場規模分析與預測
  • 各金額
• 市場佔有率分析與預測
  • 藥物的類別
    • 認證核可藥
    • 仿單標示外醫藥品
  • 各流通管道
    • 醫院藥局
    • 線上藥局
    • 零售藥局
  • 各國佔有率
    • 美國
    • 加拿大
    • 墨西哥
• 各國市場評估
  • 美國的亨丁頓舞蹈症治療藥市場展望:未來預測(2018～2032年)*
    • 市場規模的分析與預測
    • 市場佔有率的分析與預測
  • 加拿大
  • 墨西哥

全部的市場區隔，成為對象的全部的地區和被國家成為對象的全部的地區和被國家提供。

第7章 歐洲的亨丁頓舞蹈症治療藥市場未來展望 (2018～2032年)

• 德國
• 法國
• 義大利
• 英國
• 俄羅斯
• 荷蘭
• 西班牙
• 土耳其
• 波蘭

第8章 亞太地區的亨丁頓舞蹈症治療藥市場未來展望 (2018～2032年)

• 印度
• 中國
• 日本
• 澳洲
• 越南
• 韓國
• 印尼
• 菲律賓

第9章 南美的亨丁頓舞蹈症治療藥市場未來展望 (2018～2032年)

• 巴西
• 阿根廷

第10章 中東·非洲的亨丁頓舞蹈症治療藥市場未來展望 (2018～2032年)

• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 南非

第11章 需求與供給分析

第12章 進口·出口分析

第13章 價值鏈分析

第14章 波特的五力分析

第15章 大環境分析

第16章 價格分析

第17章 市場動態

• 推動市場要素
• 市場課題

第18章 市場趨勢與發展

第19章 法律規範

• 臨床試驗
• 法規當局的認證

第20章 專利的形勢

第21章 案例研究

第22章 競爭情形

• 前五名市場領導公司:競爭矩陣
• SWOT分析:前五名公司
• 主要企業的形勢:前十大企業
  • H. Lundbeck A/S
  • 企業概要
  • 主要經營團隊
  • 產品·服務
  • 財務狀況(報告為基礎的)
  • 主要市場的著重和地理存在感
  • 最近的趨勢/事業合作/聯盟/企業合併·收購 (M&A)
  • Bausch Health Companies Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Pfizer Inc.
  • Neurocrine Biosciences, Inc.
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Prilenia Therapeutics BV

以上公司並非依市佔率排序，可能會根據分析過程中收到的資訊進行調整。

第23章 策略建議

第24章 Market Xcel相關資料，免責聲明

Global Huntington's disease treatment market is projected to witness a CAGR of 12.45% during the forecast period 2025-2032, growing from USD 509.56 million in 2024 to USD 1302.78 million in 2032. The market's growth is supported by the rising cases of Huntington's disease, increasing investments towards pharmaceutical products and therapies, rising initiatives to increase awareness about the condition, and rapid advancements in medical research. As per the estimates of UC Davis Health (University of California), Huntington's disease affects about 1 in 10,000 people across the globe. Recent advancements in gene therapies and RNA therapeutics are also supporting the market's expansion.

Additionally, government and nonprofit organizations are fostering collaborations and clinical trial awareness among patients and caregivers. These efforts are not only improving trial participation rates but also accelerating drug development timelines. The market's growth is also driven by the increasing awareness among medical professionals about the ongoing clinical research and advancements in neurodegenerative diagnostics. Increasing investments in disease-modifying therapies coupled with the rising government support for the management of rare diseases is also contributing towards the market's expansion.

Advancements in Early Disease Detection and Treatment Support Market Growth

Early diagnosis and intervention are essential for the management of neurodegenerative disorders such as Huntington's disease. Modern testing techniques aid in the identification of individuals carrying Huntington's disease gene mutation, even before the occurrence of symptoms. This early identification for genetic counseling, clinical monitoring, and enrollment in clinical trials in a time-efficient manner. This in turn is allowing pharmaceutical companies to develop novel drugs, that are able to halt or slow the progression of the disease, providing lucrative growth opportunities for the market. For instance, in February 2025, Latus Bio, Inc. released data in support of its preclinical gene therapy program for Huntington's disease. The company introduced a new computational model for predicting the effects of the knockdown of MSH3 on reducing somatic instability. The company aims to use its AAV-DB-3 capsid variant for delivering an engineered mRNA to reduce the MSH3 in the cells that are affected by Huntington's disease.

Regulatory Approvals Support Market Expansion

Increasing regulatory support and approvals are propelling the market's expansion as they accelerate the adoption and accessibility of new therapeutic solutions. Regulatory bodies such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (US FDA) are granting regenerative medicine advanced therapy and breakthrough therapy to promising candidates to ensure the availability of advanced therapies and incentivize the leading pharmaceutical companies to invest in Huntington's disease treatments. The provision of such designations facilitates faster drug development and review, ensuring the entry of innovative treatments. For instance, in April 2025, the US FDA granted breakthrough therapy designation to AMT-130 for treating Huntington's disease. Unlike current therapies available in the market, AMT-130 aims to address the underlying genetic cause of the condition and provide long-term solutions for Huntington's. As new drugs and gene therapies progress through clinical stages, the market is expected to expand rapidly, due to improved clinical outcomes and patient access.

Hospital Pharmacies Hold Significant Share of the Market

The segment's dominance is supported by the central role played by hospital pharmacies in the management of complex diseases such as Huntington's disease. A large portion of Huntington's disease medications, including deutetrabenazine and tetrabenazine, often necessitate close medical supervision and are prescription-only. Hospital pharmacies are well-equipped to ensure that both outpatients and inpatients have access to the necessary drugs and are often under the care of multidisciplinary teams such as genetic counselors, neurologists, and psychiatrists. Moreover, hospital pharmacies offer comprehensive services including medication monitoring, management of side effects, and adjustments to treatment regimens, which are crucial for Huntington's disease patients who may experience rapid changes in symptoms.

Meanwhile, leading hospital pharmacies are focusing on expanding their market presence, contributing to the segment's expansion. For instance, in March 2025, Apollo HealthCo Ltd, operator of the online platform Apollo 24/7 and Apollo Pharmacy, announced the expansion of its offline hospital pharmacy network in Bengal, India.

North America Holds a Major Market Share

The region's dominance can be attributed to the strong presence of leading pharmaceutical companies, high investments in research activities, and increasing cases of Huntington's disease in countries such as the United States and Canada. As per the estimates of the Huntington's Disease Society of America, approximately 41,000 Americans have Huntington's, and 200,000 Americans are at risk of inheriting the disease.

The market also benefits from favorable reimbursement policies and high levels of awareness among clinicians and the general population. The US FDA's stance on gene therapies and orphan drugs incentivizes companies to pursue treatments for Huntington's disease. Furthermore, organizations such as Huntington's Disease Society of America and the Hereditary Disease Foundation play a key role in advocacy, funding, and education. Canada, too, is witnessing a rise in Huntington's disease research with several centers of excellence and registry programs promoting real-world data collection. The region also benefits from numerous clinical trials and significant investments in neurodegenerative diseases.

Impact of the U.S. Tariffs on Global Huntington's Disease Treatment Market

The financial strain from the tariffs may divert resources away from research and development activities, forcing companies to scale back on or postpone clinical trials for Huntington's disease therapies due to rising operational costs. This could result in delays in the availability of novel therapeutic solutions and could slow the progress of promising treatments, including gene therapies, which are currently under various stages of development. In response to the tariffs, leading pharmaceutical companies are considering reshoring their manufacturing sites to the United States and diversifying their supply chains. The uncertainties surrounding the trade policies are also deterring investments in Huntington's research, impacting the market's expansion.

Key Players Landscape and Outlook

The key players in the market are actively focusing on developing novel therapeutic solutions that target the root cause of the disease and its progression and provide symptomatic relief. Additionally, the companies are also engaging in mergers and acquisitions to enhance their neurodegenerative pipeline. For instance, in December 2024, H. Lundbeck A/S completed the acquisition of Longboard Pharmaceuticals, Inc., allowing the company to expand its Huntington's portfolio. With Lundbeck's established expertise in neurology and global reach, Longboard's neflamapimod can be efficiently developed, commercialized, and made accessible to a broader patient base. Such acquisitions are expected to support the leading players in the market in expanding their customer base and strengthening their position in the market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Huntington's Disease Treatment Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drug Type
    • 5.2.1.1. Approved Drugs
      • 5.2.1.1.1. Tetrabenazine
      • 5.2.1.1.2. Deutetrabenazine
      • 5.2.1.1.3. Valbenazine
    • 5.2.1.2. Off-Label Drugs
      • 5.2.1.2.1. Antipsychotics
      • 5.2.1.2.2. Antidepressants
  • 5.2.2. By Distribution Channel
    • 5.2.2.1. Hospital Pharmacies
    • 5.2.2.2. Online Pharmacies
    • 5.2.2.3. Retail Pharmacies
  • 5.2.3. By Region
    • 5.2.3.1. North America
    • 5.2.3.2. Europe
    • 5.2.3.3. Asia-Pacific
    • 5.2.3.4. South America
    • 5.2.3.5. Middle East and Africa
  • 5.2.4. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Drug Type
  • 5.3.2. By Distribution Channel
  • 5.3.3. By Region

6. North America Huntington's Disease Treatment Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Drug Type
    • 6.2.1.1. Approved Drugs
      • 6.2.1.1.1. Tetrabenazine
      • 6.2.1.1.2. Deutetrabenazine
      • 6.2.1.1.3. Valbenazine
    • 6.2.1.2. Off-Label Drugs
      • 6.2.1.2.1. Antipsychotics
      • 6.2.1.2.2. Antidepressants
  • 6.2.2. By Distribution Channel
    • 6.2.2.1. Hospital Pharmacies
    • 6.2.2.2. Online Pharmacies
    • 6.2.2.3. Retail Pharmacies
  • 6.2.3. By Country Share
    • 6.2.3.1. United States
    • 6.2.3.2. Canada
    • 6.2.3.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Huntington's Disease Treatment Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.1.1. Approved Drugs
        • 6.3.1.2.1.1.1. Tetrabenazine
        • 6.3.1.2.1.1.2. Deutetrabenazine
        • 6.3.1.2.1.1.3. Valbenazine
        • 6.3.1.2.1.2. Off-Label Drugs
        • 6.3.1.2.1.2.1. Antipsychotics
        • 6.3.1.2.1.2.2. Antidepressants
      • 6.3.1.2.2. By Distribution Channel
        • 6.3.1.2.2.1. Hospital Pharmacies
        • 6.3.1.2.2.2. Online Pharmacies
        • 6.3.1.2.2.3. Retail Pharmacies
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Huntington's Disease Treatment Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Huntington's Disease Treatment Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Huntington's Disease Treatment Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Huntington's Disease Treatment Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Import and Export Analysis

13. Value Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

• 17.1. Market Drivers
• 17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework

• 19.1. Clinical Trials
• 19.2. Regulatory Approvals

20. Patent Landscape

21. Case Studies

22. Competitive Landscape

• 22.1. Competition Matrix of Top 5 Market Leaders
• 22.2. SWOT Analysis for Top 5 Players
• 22.3. Key Players Landscape for Top 10 Market Players
  • 22.3.1. H. Lundbeck A/S
    • 22.3.1.1. Company Details
    • 22.3.1.2. Key Management Personnel
    • 22.3.1.3. Products and Services
    • 22.3.1.4. Financials (As Reported)
    • 22.3.1.5. Key Market Focus and Geographical Presence
    • 22.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 22.3.2. Bausch Health Companies Inc.
  • 22.3.3. Sun Pharmaceutical Industries Ltd.
  • 22.3.4. Teva Pharmaceuticals Industries Ltd.
  • 22.3.5. Dr. Reddy's Laboratories Ltd.
  • 22.3.6. Pfizer Inc.
  • 22.3.7. Neurocrine Biosciences, Inc.
  • 22.3.8. Hikma Pharmaceuticals PLC
  • 22.3.9. Lupin Limited
  • 22.3.10. Prilenia Therapeutics B.V.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

23. Strategic Recommendations

24. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 2. Global Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 3. Global Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 4. Global Huntington's Disease Treatment Market Share (%), By Region, 2018-2032F
• Figure 5. North America Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 6. North America Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 7. North America Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 8. North America Huntington's Disease Treatment Market Share (%), By Country, 2018-2032F
• Figure 9. United States Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 10. United States Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 11. United States Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 12. Canada Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 13. Canada Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 14. Canada Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 15. Mexico Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 16. Mexico Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 17. Mexico Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 18. Europe Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 19. Europe Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 20. Europe Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 21. Europe Huntington's Disease Treatment Market Share (%), By Country, 2018-2032F
• Figure 22. Germany Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 23. Germany Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 24. Germany Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 25. France Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 26. France Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 27. France Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 28. Italy Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 29. Italy Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 30. Italy Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 31. United Kingdom Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 32. United Kingdom Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 33. United Kingdom Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 34. Russia Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 35. Russia Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 36. Russia Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 37. Netherlands Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 38. Netherlands Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 39. Netherlands Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 40. Spain Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 41. Spain Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 42. Spain Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 43. Turkey Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 44. Turkey Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 45. Turkey Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 46. Poland Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 47. Poland Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 48. Poland Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 49. South America Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 50. South America Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 51. South America Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 52. South America Huntington's Disease Treatment Market Share (%), By Country, 2018-2032F
• Figure 53. Brazil Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 54. Brazil Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 55. Brazil Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 56. Argentina Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 57. Argentina Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 58. Argentina Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 59. Asia-Pacific Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 60. Asia-Pacific Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 61. Asia-Pacific Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 62. Asia-Pacific Huntington's Disease Treatment Market Share (%), By Country, 2018-2032F
• Figure 63. India Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 64. India Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 65. India Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 66. China Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 67. China Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 68. China Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 69. Japan Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 70. Japan Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 71. Japan Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 72. Australia Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 73. Australia Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 74. Australia Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 75. Vietnam Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 76. Vietnam Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 77. Vietnam Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 78. South Korea Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 79. South Korea Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 80. South Korea Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 81. Indonesia Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 82. Indonesia Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 83. Indonesia Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 84. Philippines Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 85. Philippines Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 86. Philippines Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 87. Middle East & Africa Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 88. Middle East & Africa Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 89. Middle East & Africa Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 90. Middle East & Africa Huntington's Disease Treatment Market Share (%), By Country, 2018-2032F
• Figure 91. Saudi Arabia Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 92. Saudi Arabia Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 93. Saudi Arabia Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 94. UAE Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 95. UAE Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 96. UAE Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 97. South Africa Huntington's Disease Treatment Market, By Value, In USD Million, 2018-2032F
• Figure 98. South Africa Huntington's Disease Treatment Market Share (%), By Drug Type, 2018-2032F
• Figure 99. South Africa Huntington's Disease Treatment Market Share (%), By Distribution Channel, 2018-2032F
• Figure 100. By Drug Type Map-Market Size (USD Million) & Growth Rate (%), 2024
• Figure 101. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2024
• Figure 102. By Region Map-Market Size (USD Million) & Growth Rate (%), 2024